). A␤ effect ( Figure 1D ). Quantification of apoptotic nuclear treatment did not substantially increase the mRNA level morphology showed a significant effect of blocking Fasof any of these TIMPs. The impact on A␤ neurotoxicity of TIMP-1, TIMP-2, and TIMP-3 versus GM6001 was investigated in the experiment shown in Figure 3F . Sur-4 Correspondence: dgreen5240@aol.com
FasL can be shed from cells by metalloproteinases,
binding motif in their catalytic domains [10] . Although and this process greatly reduces its proapoptotic acthe inclusion of GM6001 had little effect on CGN cultures tivity [4, 5] . Here, we show that factors affecting the after 4 days, it acted synergistically with A␤ to dramatishedding of membrane-bound FasL significantly imcally increase neurotoxicity starting at 2 days (Figure pact A␤ neurotoxicity. A broad-spectrum metallo-3A). Membrane-bound (i.e., unshed) FasL protein was proteinase inhibitor, GM6001/Ilomastat, acted synerfound to increase after treatment with A␤ and GM6001 gistically with A␤ to enhance neurotoxicity through a ( Figure 3B ). A␤ alone increased the relative expression FasL-dependent mechanism. The disruption of ADAMof FasL 1.6-fold by 2 days, while the combination of A␤ based metalloproteinase activity was likely responsiand GM6001 more than tripled (3.1ϫ) membrane-bound ble, as MMP-inhibiting TIMPs had no such effect. In FasL levels. Conversely, A␤ plus recombinant MMP-7 contrast, enhanced FasL shedding, by recombinant decreased the level of membrane-bound FasL (0.7ϫ) MMP-7, completely protected neurons from A␤ neurobelow that of media-treated controls.
toxicity. These findings suggest that factors that affect
We then compared the GM6001 response in neurons metalloproteinase-mediated shedding of FasL may from WT and FasL-defective gld mice ( Figure 3C ). After play a role in the etiology of Alzheimer's disease and 5 days, GM6001 dramatically enhanced the neurotoxic may provide an avenue for therapeutic intervention.
effects of A␤ in WT cultures, but it did not affect the resistance of gld neurons to A␤. Similarly, CGNs cultured Results and Discussion with FasFc were protected from the synergistic effects of A␤ and GM6001 ( Figure 3D ). In contrast, TNFR(p60)Fc To examine the role of Fas-FasL interactions in A␤- [6] had no protective effect. These findings indicate that mediated neuronal death, we employed recombinant FasL-mediated cell death is responsible for the synerFasFc to block FasL function [6] . CGN cultures treated gistic effects observed with A␤ and GM6001. with A␤ 1-40 for 5 days displayed significant neurotoxicity, We next examined if decreased FasL shedding might as indicated by increased percentages of apoptotic nube facilitated by higher expression of naturally occurring clei ( Figures 1A and 1B) . However, cultures treated with tissue inhibitors of metalloproteinases (TIMPs). We as-A␤ in combination with FasFc were protected from A␤ sessed RNA levels of the four known mammalian TIMPs neurotoxicity ( Figure 1C ), while control IgG had no such
[11] in CGN cultures treated with A␤ ( Figure 3E ). A␤ effect ( Figure 1D ). Quantification of apoptotic nuclear treatment did not substantially increase the mRNA level morphology showed a significant effect of blocking Fasof any of these TIMPs. The impact on A␤ neurotoxicity of TIMP-1, TIMP-2, and TIMP-3 versus GM6001 was investigated in the experiment shown in Figure 3F . Sur- Real-Time PCR Neuron cultures were rinsed three times with PBS, and then total RNA was isolated with 400 l Trizol-LS. Reverse-transcribed cDNA was made from 1 g of each RNA sample and was used for all subsequent real-time PCR reactions. Specific primer sequences are available upon request. Cycles were run on a PE Biosystems Taqman, and CYBR green was used for fluorescent detection of dsDNA, as per the manufacturer's instructions. Normalization of the initial RNA composition was calculated from concurrent runs with primers specific for actin. Triplicates were performed with each primer set for each RNA sample. The mid-linear range was used to establish the threshold for each oligonucleotide set. After normalization and the calculation of differences within each time-point experiment subset, all data from each time point were pooled to calculate differences.
A␤ Treatments A␤ 1-40 was purchased from BachemAG, resuspended in water to 6 mg/ml, then diluted to 1 mg/ml with PBS and allowed to preincubate at 37ЊC for 3-5 days before use. Preincubated peptide was added to neurobasal media to achieve 25, 50, 75, or 100 g/ml A␤, and it was placed on cells for 1-5 days. In FasFc studies, cultures were preincubated in media with 30 M FasFc or IgG for 12 hr, and 30 M was also added to the treatment media. Recombinant human MMP-7 (Calbiochem) was diluted into treatment media at 1.5 and 15 U/ml immediately prior to use. GM6001 (Chemicon) was used at final concentrations of 22-25 M. Recombinant human TIMP-1 (Chemicon), recombinant human TIMP-2 (Chemicon), and recombinant mouse TIMP-3 (Chemicon) were used at final concentrations of 500 ng/ml. were incubated for 1 hr at room temperature. Three 5-min washes in C57BL/6J and congenic B6smn.C3H-FasLϽgldϾ mice from Jack-PBST were followed by chemiluminescent exposure of film. Relative son Labs were used for cerebellar neuron preparations at 7 days FasL levels were determined from scanned films and were analyzed of age. Cerebellum tissue was minced with a razor and incubated with NIH image, normalized to corresponding anti-actin blots. in 0.05% trypsin/EDTA in PBS (0.25% sucrose) for 7 min. Trypsin inhibitor was added, and material was pelleted at 1000 ϫ g for 3 min. Pellets were washed in 15 ml PBS (0.25% sucrose). The final Reagents Anti-FasL antibodies (Oncogene, used at 1:50) were employed for pellets were resuspended in 1 ml PBS (0.25% sucrose) and were triturated with coarse, then fine, fire-polished Pasteur pipettes. Cells immunoblots, and the identity of the FasL band that was resolved was confirmed (not shown) with other anti-FasL antibodies (Pharwere diluted in 10 ml complete neurobasal media (see below) and were drained through a 70 M sieve. Viable cells were assessed by mingen, used at 1:1000; Santa Cruz Biotech, used at 1:1000). HRPconjugated secondary antibodies were purchased from Amersham trypan blue exclusion and were plated onto poly-L-lysine-coated plates in neurobasal media containing B27 supplement (Invitrogen), (used at 1:2000) and Pierce (used at 1:10000). Chemiluminescent reagents were purchased from Pierce; Neurobasal media, B27 sup-25 mM KCl, penicillin, streptomycin, and L-glutamine at 2.5 ϫ 10 5 / cm 2 . Cytosine arabinoside (5 M) was added after 48 hr, and half plement, penicillin, streptomycin, L-glutamine, and RT reagents were purchased from GIBCO. Poly-L-lysine was purchased from the media was changed every 2 days thereafter. Cultures were con- from samples containing recombinant MMP-7 show the extent of (E and F) The inclusion of recombinant human MMP-7 (1.5 U/ml) shedding that accompanied total rescue from A␤ neurotoxicity. Note eliminated any detectable A␤-mediated apoptosis.
that more sFasL was detected in the A␤ϩMMP-7 cultures versus (G and H) Conversely, the inclusion of GM6001 (22 M) exacerbated MMP-7 alone, due to the increased FasL expression triggered by A␤ neurotoxicity, as almost every nucleus appeared apoptotic.
A␤. The Ponceau-stained blot prior to blocking is shown in the bottom panel.
